Nanomerics "switches on" drugs
Nanomerics uses leading know-how in pharmaceutical nanotechnology to overcome the limitations of current drugs to develop products that deliver patient benefit in areas of unmet medical need.
NM133 is a nano enabled form of cyclosporine A that is being investigated for the treatment of dry eye disease.
NM127 is a strong pain therapeutic based on an endogenous peptide and could replace the current opiate analgesics.
NM147 is a oral form of the Amphotericin B indicated for the treatment of various fungal infections and leishmaniasis.
Nanomerics has a number of other products in its development pipeline
Molecular Envelope Technology (MET)
MET is based on a proprietary polymer with tightly controlled chemical properties engineered to form defined nano-sized drug carriers.
MET polymers form polymeric micelles which are extremely stable, predictable and carry high API payloads.
MET is regarded as safe as particles gradually disintegrate resulting in complete polymer excretion.
MET particles increase delivery of APIs across a number of epithelial barriers by between 5-40 fold.